EGFRvIII Has the First Therapeutic Target in GBM Finally Been Revealed?

For Nearly 1 in 3 GBM Patients This Hidden Threat May Offer a Potential Therapeutic Target.

Cellnex Therapeutics Is Currently Investigating EGFRvIII as a Potential Therapeutic Target in GBM

Take a closer look at the ongoing research being performed by Cellnex Therapeutics on EGFRvIII and its role as a promising target in the treatment of GBM at www.cellnex.com.

References: